FDA approves Telix brain cancer imaging drug Pixclara for glioma PET scans

• FDA cleared Telix’s Pixclara, an F-18 PET imaging drug for glioma, marking the first approved FET-PET agent in the US.
• Label covers adults, pediatric patients from 1 month old, to help distinguish recurrent or progressive glioma from treatment-related changes.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telix Pharmaceuticals Ltd. published the original content used to generate this news brief on September 14, 2026, and is solely responsible for the information contained therein.